Uric acid is 2,6,8-trihydroxypurine, and seems to be present in almost all organisms. In snakes, reptiles, birds and spiders it is the main end-product of all nitrogenous metabolism, and these groups of animals have kidneys which are capable of secreting large amounts of uric acid. This is then excreted as a slurry of crystals, which confers the advantage that the nitrogenous end-product can be excreted with very little water, a benefit in arid environments. In contrast, the excretion of urea necessitates the loss of a relatively larger quantity of water, the size of which is dependent upon the concentrating ability of the kidney.
In mammals, uric acid is the end-product only of purine metabolism and is formed by the breakdown of purine nucleotides, which are derived from DNA and RNA, and also from other compounds important in general metabolism, such as ATP, ADP and AMP, FAD, coenzyme A and S-adenosylmethionine. In mammals, with the exception of man and closely related primates, uric acid is further broken down to allantoin by the enzyme uricase. The advantage of this is that allantoin is a very soluble compound, whereas uric acid is very insoluble.
At physiological pH only the hydroxyl group at the 8 position, which has a pK of 5 4, dissociates. Therefore, in blood and tissue fluids uric acid is overwhelmingly (98%) in the dissociated form of Ur-, so that effectively in tissue fluids the predominant form is Na+Ur-, with smaller amounts of K+Ur-etc. In the urine, in contrast, as the physiological range of pH is 4-7 to 8-0, the proportion of HUr to Ur-varies greatly; in most acid urines the form is predominantly the undissociated acid. This is many times less soluble in water than sodium urate, hence the great variation in the capacity of urine of various pHs to dissolve uric acid (Fig. 1) .
The toxicity of and the pathological changes caused by uric acid are entirely the consequences of its insolubility. This would not matter so much, except perhaps for a tendency to form crystals or stones in acid urine, were it not for one other peculiarity which primates also display, namely that the renal tubule reabsorbs around 90% of the filtered urate. There is great variation between different mammals in the renal handling of uric acid,' from net secretion with uric acid clearances two to three times the glomerular filtration rate, as in the pig and some rabbits, down to man, who has a net reabsorption of uric acid in the renal tubule higher than any other mammal except closely related primates. The result of the deletion of the enzyme uricase and the extensive tubular reabsorption of uric acid is that the concentration of uric acid in human body fluids is not far off the limit of solubility in plasma at 37°C (about 0 45 mmol/l), especially in males, who have a higher level of plasma uric acid than children or premenopausal females. This contrasts sharply with other mammals whose plasma uric acid is, in general, less than O 03 mmol/l: in the pig it is as low as O0002 mmol/l. The evolutionary advantage of this production and retention of uric acid is not clear, especially as it carries with it the risk of gouty disease.
C1c6meron, Simmonds consequences.2 It includes filtration, followed by a bidirectional tubular transport system involving reabsorption, secretion and finally postsecretory reabsorption (Fig. 2) . The exact sites of these transport systems within the nephron are not known, and they may coexist extensively throughout the proximal tubule. It is likely that the brief account given here will have to be changed in the future.
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Fig (Fig. 3) the plasma is still, on average, only about twice normal even in individuals with terminal uraemia.10 As renal failure progresses the urinary excretion of urate falls steadily, but much more slowly than would be predicted from the fall in the glomerular filtration rate, so that in terminal uraemia it is only one-half or one-third normal." Evidently the net tubular reabsorption of urate must fall from the normal value of about 90% in health, to as little as 20 % in terminal uraemia. Correspondingly, the excreted fraction increases from 10% to as much as 80% of that filtered.12 How this adaptation occurs is not clear, and is unlikely to be settled until there is more accurate information on the tubular handling of urate in health. Some compounds retained in uraemia are uricosuric for example, hippurates, and these may be the factors responsible for this aspect of adaptation to the uraemic state.
Even so, the reduction in total excretion of urate suggests either that urate production is reduced or that some extrarenal excretion increases as renal function declines. Although there has been some controversy, and data are not extensive, the consensus from studies using '4C-urate is that urate production in uraemia is normal. Also, it is known that in health some urate, probably one-third, but perhaps as little as one-tenth of the total production, is excreted into the gut and degraded there by uricase-bearing bacteria. This almost certainly increases in uraemia, although direct information on this point is limited to the study of two patients.
ROLE OF THE KIDNEY IN THE GENESIS OF GOUT
One hundred and thirty-two years ago, Garrod speculated that the cause of gout might be "a loss of power ... in the uric acid excretory function of the kidney." Before we can examine the suggestion that gout-or at least some gouty patients-suffer from a disorder of urate excretion, we must examine briefly the origins of uric acid. The body pool of urate, and hence the plasma urate concentration, is the result of a balance between production, ingestion, and excretion (Fig. 6) . Ingested nucleotides and purines are largely degraded by gut and liver enzymes, whilst endogenous purine synthesis matches that incorporated into tissue nucleotides RNA and DNA. The synthesis of each molecule of purine req uires the consumption of six molecules of ATP, but the bulk of the purine bases released from nucleotide degradation are "salvaged" for new nucleotide synthesis by the expenditure of a single molecule of ATP, principally through the agency of the enzyme hypoxanthine-guanine phosphoribosyl transferase (HGPRT, EC 2.4.2.813). The free nucleotides are powerful inhibitors of de novo purine synthesis, and thus this enzyme functions as part of an inhibitory pathway limiting and regulating purine synthesis, restricting the availability of pyrophosphate-ribose phosphate (PP-ribose-P) in the process. The possible causes of increased plasma urate concentration are (i) overproduction of endogenous purine, (ii) increased intake of exogenous dietary purine, (iii) decreased excretion of purine.
Purine production can be measured using the incorporation of radiolabelled precursors, but such methods are not suitable for use in routine clinics. A simpler way of assessing the de novo production of purines is to place the patient on a purine-free diet for five to seven days and measure the urinary excretion of urate, since by this time purine excretion will equal endogenous production. In this way less than 100% of patients with gout have been found to excrete an abnormally large amount of urate ( >4 mmol/day). In most of these the overproduction is modest, but in a few individuals great quantities of urate are produced-up to 5 or even 10 times normal. In some of these patients abnormalities of purine enzymes can be discerned, the best-known of which is the Lesch-Nyhan syndrome due to the absence or partial absence of the regulatory salvage enzyme HGPRT.13 Most of the hemizygotes for this deficiency are mentally defective and exhibit athetosis and a remarkable, bizarre tendency to selfmutilation. Others (and all heterozygotes) are much less affected, and may present as otherwise normal gouty overproducers of urate. Another enzyme, PP-ribose-P synthetase (EC 2.7.6.1.), may be present in a mutant form which has increased activity, and which consequently accelerates purine synthesis. This condition, like the Lesch-Nyhan syndrome, is inherited as a sex-linked recessive trait since the DNA coding for the enzyme is carried on the X chromosome.
Purine ingestion has been known for millenlia to be high in subjects with gout, as the popular stereotype of the gouty subject shows. Gout is a disorder of affluent societies with diets rich in purines; during times of hardship uric acid concentrations fall and clinical gout almost vanishes. These observations, and the extensive data on the increase in urinary purine and plasma urate concentrations in normal and gouty subjects on increasing purine intake, show the importance of dietary purine in precipitating clinical gout. The nature of the ingested purine may be more important than is realised, as some forms of purine for example, from RNA, are absorbed and catabolised more readily than others.
However, neither overproduction (tinless sudden and massive) nor overingestion are likely to raise the concentration of urate in the plasma, if the renal response is normal. When normnal subjects have their urate production reduced by the administrationi of allopurinol, or raised by ingestion of yeast, which is rich in RNA, then the plasma urate rises little with increased intake, the increase in the excretion of urate being dramatic when the rise in plasma urate is modest (Fig. 7) . When the same studies are undertaken on gouty subjects, an immediate difference is apparent (Fig. 7) , some of which comes from the inclusion of normo-and hyperexcretors of tirate. The striking difference is that for any plasma urate concentration, the gouty patients' excretion of urate was consistently less than in the normal sLibjects. Looked at another way, these data demonstrate that to generate the same excretion of urate, the gouty patient must "run" a higher plasma urate concentration.
The This raises the unsolved question of why clinical gout is not commoner than it is in patients with raised plasma urate as a result of renal failure. Two possible explanations have been advanced, neither of which is convincing. One suggests that urate is more soluble in uraemic than in normal plasma, the other that the inflammatory response normally evoked by urate crystal deposition is muted by the immunosuppression associated with uraemia.
The kidney also seems to be the site of the difference between men and women in their liability to gout. The female kidney excretes a higher proportion (10-12%) of filtered urate than the male kidney (8-10 %), which gives males their higher plasma urate Urinary abnormalities such as mild proteinuria and abnormalities of urinary sediment are commnon in gouty patients, but although renal failure was common and one of the principal causes of death from gout until 20-30 yr ago, it is now rare.'5 16 The cause of renal faiiure in gout has been much debated. Some suggest that all the renal damage follows the associated vascular disease of gout,15 while others see a central role for the deposition of uric acid or urate crystals within the kidney, which is the only feature specifically associated with gout.14 The reasons for the decline in the mortality from renal failure in gout are now impossible to determine, but it is tempting to relate them to the decreasing frequency of the disease associated with moderation of purine intake and with the more effective treatment of the disease, first with uricosuric agents and then with allopurinol. Today, gross deforming tophaceous gout is a rarity, and associated hypertension will normally receive effective treatment.
The nature of "gouty nephropathy"-or even its existence as such-has been the subject of much debate. On the clinical side there is no doubt that some patients with classical gout-men of middle age with a high purine intake in the form of food or beer suffer a gradual decline in renal function which can be arrested by control of their plasma urate concentrations using allopurinol. However, a number of such patients are also hypertensive, and in many it is difficult to assess the relative importance of treating hyperuricaemia and hypertension. Equally, it is clear that this type of patient is now less common, and the decline in numbers of this formerly common group has brought another group of gouty patients with renal failure into prominence. These are young patients aged between 20-40 yr with precocious onset of gout in childhood, or early adult life, in whom renal failure is an early feature, men and women being affected equally. A family history of gout is common in this group, and in some of these families hypertension is absent initially, so it seems clear that this cannot be the feature causing the renal failure. Renal biopsies show an interstitial nephropathy with tubular atrophy and glomerulosclerosis, but urate crystals are rare.'7 Experimentally, it has been shown that crystal nephropathies due to various purines, including xanthine and uric acid, can cause interstitial scarring as a long-term result.18 At this point the question of sodium urate and uric acid must be raised. In the interstitium of the kidney the ambient pH is that of plasma, and the predominant species of purine is the needle-shaped sodium urate. Within the tubules, however, the pH may be 5 0 or less and the predominant species will be amorphous uric acid, and there is no doubt that the predominant lesion in patients with acute overproduction of urate due to treatment with cytotoxic drugs (discussed below) is intratubular deposition of uric acid. The origin of the interstitial amorphous sodium urate in chronic gout nephropathy is controversial. Some see it as the result of the ambient plasma urate concentration, others (including ourselves) as the result of erosion of uric acid crystals out of the tubules with subsequent transformation to sodium urate. Both mechanisms may be operative; in any case, both uric acid and sodium urate are capable of generating inflammation with secondary scarring.
This argument is not merely academic, because if the primary abnormality is the deposition of sodium urate interstitially, appropriate treatment is to lower the plasma urate concentration and the method of achieving this is unimportant. If, on the other hand, the initial event is the intratubular deposition of uric acid crystals, then the tubular concentration of uric acid will be seen as the crucial event, and uricosuric agents will be contraindicated. It seems best therefore in patients with gout and renal impairment to reduce urate production with allopurinol, which should be effective in either case. It must be remembered, however, that its active metabolite, oxipurinol, even in patients with normal kidney function, has a long half-life since, unlike its parent drug, it is reabsorbed in the tubules; and the dose of allopurinol may have to be reduced to as little as 100 mg daily or even 100 mg three times weekly in advanced renal failure, to minimise the risk of bone marrow depression.
In some patients, even control of both hypertension and plasma urate concentration fails to arrest a decline in renal function, and this again raises the question of exactly what determines the appearance, severity and progression of interstitial nephropathy in gouty patients. It seems likely that there are several groups which can be identified rather tentatively, some of which respond to available treatment. Even so, the central fact is that, today, chronic renal failure is rare in gout. Gout is the primary cause of renal failure in less than 1 % of patients treated by regular dialysis or transplantatiort in Europe as a whole, or even in our own unit which has a particular interest in gouty nephropathy. '9 Fortunately, the acute hyperuricaemic renal failure20 which occurs most commonly when there is massive overproduction of purines as a result of tissue breakdown, also is becoming rare. The commonest circumstance is the treatment of leukaemia, lymphoma or myeloma, but rare instances after spontaneous remission or the treatment of solid tumours have been recorded. The appearance of renal failure can be averted in almost all cases by ensuring a high volume of alkaline urine by means of a high fluid intake coupled with a diuretic and sodium bicarbonate, and above all, by giving allopurinol to distribute the purine load over the three purines hypoxanthine, xanthine and uric acid, through its action in blocking xanthine oxidase. Whilst hypoxanthine is very soluble, xanthine is as insoluble as uric acid in neutral and acid urine but its solubility does not increase in alkaline urine. A few cases of xanthine stones or xanthine nephropathy have been reported in patients treated for malignancies with allopurinol, and also occasionally in other patients with gross overproduction of urate, such as the Lesch-Nyhan syndrome, treated similarly.
URIC ACID STONES
Urate is least soluble in the form of uric acid in acid urines (Fig. 1 ). An interesting observation is that many patients with gout, but otherwise normal renal function, pass urine with a low pH in the range 4 8-5 4 throughout the 24 hours of the day. This contrasts with normal individuals, who, depending on their diet, show a pH above 6 at some time in the day as part of diurnal variation. A persistently low urine pH is also seen in some non-gouty uric acid stone-formers, and is associated with a defective tubular secretion of ammonium, the mechanism of which is obscure10 the often-quoted idea that this results from diversion of glutamate from ammonium to urate production has been shown to be untenable on quantitative grounds. In young patients with gout, stone formation often precedes the onset of the arthritis.
The importance of the acid urine in predisposing to the formation of urate stones is clear, as Fig. shows. Obvious steps in treatment are: (i) to increase urine volume, (ii) to increase the pH of the urine, (iii) to reduce urinary urate excretion by allopurinol. In practice, the first two alone usually suffice2l but it is important to realise that sodium itself, given as sodium bicarbonate, actually decreases the solubility of urate in the urine, by a common ion effect. It is important, therefore, to ensure that the urine volume is greatly increased, since the solubility of urate in the urine increases as the square of the volume, again because of interaction with other ions.
An interesting observation is that gouty patients also have an increased tendency to form oxalate stones. This may be related to competition by excess uric acid for inhibitors of crystallisation in the urine, or to the action of uric acid crystals as nuclei for the crystallisation of the calcium oxalate; but an effect of purine metabolism on oxalate production is also possible. In passing we can note that in addition to uric acid and xanthine, an even more insoluble purine, namely 2,8 dihydroxyadenine, (2,8- Finally, the dangers of combined treatment with allopurinol and purine analogues needs to be mentioned. Both azathioprine and its metabolite, 6-mercaptopurine are oxidised to thiouric acid by xanthine oxidase, and allopurinol prolongs the actions of the drugs indefinitely. Even more interestingly, in cyclophosphamide-treated patients leucopenia is more frequent in patients also given allopurinol.
